Advertisement

Volume 134, Issue 8

 

 

August 22, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Novel mechanism of action of tick salivary anticoagulant. See the article by
De Paula et al
.

NMR structure determination of Ixolaris and factor X(a) interaction reveals a noncanonical mechanism of Kunitz inhibition
De Paula and colleagues investigated the mechanism of action of Ixolaris, an anticoagulant secreted by ticks to facilitate blood sucking. They elucidate a novel mechanism of factor Xa inhibition that does not depend on binding directly to the active site but rather causes allosteric changes that inhibit Xa–tissue factor interaction.


ETV6-related thrombocytopenia and leukemia predisposition
In a Blood Spotlight dealing with hematologic disease predisposition, Di Paola and Porter provide an overview of the clinical and molecular features of the syndrome associated with germline ETV6 mutation, highlighting potential pathophysiologic mechanisms for the highly penetrant thrombocytopenia as well as the characteristics of the frequent development (30%) of hematologic malignancy.


Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Usmani et al report that rapid subcutaneous administration of daratumumab over 30 minutes in relapsed multiple myeloma appears to have a good safety profile and efficacy equal to that of an intravenous infusion over several hours.


Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease with a poor outcome. Taylor and colleagues use pooled data from 3 centers to assess the clinical characteristics and outcomes of BPDCN patients that can provide a benchmark for evaluating novel therapies.

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.